Helix BioPharma to Present Clinical Trial and NASDAQ Uplisting Plans at Q3 Investor Summit

Helix BioPharma Corp. will present at the Q3 2025 Investor Summit Virtual on September 16, 2025, focusing on key corporate milestones including clinical trial preparations and a planned NASDAQ listing. The company will detail its ongoing work for a Phase Ib/Randomized Phase II clinical study of L-DOS47 combined with pembrolizumab as a first-line treatment for non-small cell lung cancer (NSCLC), a significant advancement given NSCLC's prevalence and treatment challenges.

CEO Thomas Mehrling, MD, PhD, will lead the presentation, which also covers Helix's strategy to uplist to NASDAQ in Q1 2026, aiming to enhance visibility and access to global capital markets. This move aligns with the company's broader goal of accelerating oncology asset development to transform hard-to-treat cancers into manageable conditions. Investors can register for the event at https://investorsummitgroup.fillout.com/t/8CZGk3gSQbus and access the webcast via https://investorsummitgroup.com/presentor/q3-track-1-helix-biopharma-corp/.

The implications of these announcements are substantial for both medical and investment communities. The clinical progress with L-DOS47, an antibody-enzyme conjugate targeting CEACAM6-expressing tumors, could improve outcomes for NSCLC patients by increasing sensitivity to existing therapies. Simultaneously, the NASDAQ uplist intends to position Helix for sustained growth, potentially attracting more institutional investment and supporting further research into its pipeline, which includes pre-IND candidates like LEUMUNA for post-transplant leukemia relapse and GEMCEDA, an oral gemcitabine prodrug.

This presentation at the Investor Summit, an exclusive event for small and microcap companies, underscores Helix's commitment to transparency and engagement with serious, long-term investors. The combination of clinical milestones and financial strategy highlights the company's integrated approach to addressing unmet needs in oncology while building a robust corporate foundation for future success.